Novogene to Power Cancer, Rare Disease, and Environmental Research with PacBio Sequencing

Core Insights - PacBio's Revio long-read sequencing system is being utilized by Novogene to enhance its new lab in Munich, Germany, aimed at serving the European scientific community [1][2] - The Revio system offers increased accuracy and throughput, enabling cost-effective in-depth genomic research across various fields including rare diseases, cancer, microbes, and agriculture [1][2] Company Overview - PacBio is a leading life science technology company focused on developing advanced sequencing solutions to address complex genetic problems, utilizing both HiFi long-read and SBB short-read sequencing technologies [4] - Novogene is a prominent provider of genomic services with significant sequencing capacity and expertise, operating globally with nearly 2,000 employees and a strong publication record [7] Strategic Developments - The new lab at the Innovation and Start-Up Center for Biotechnology in Munich will serve as a strategic hub for Novogene's European operations, complementing its existing global network [2] - Novogene anticipates high demand for the Revio system particularly in the rare disease and cancer research sectors, due to its ability to detect complex genomic features that other technologies may miss [2][3] Technological Advancements - The Revio system is expected to enhance the efficiency of genomic research by integrating more automation into its workflows, making long-read data more accessible to a broader customer base [2] - The collaboration between PacBio and Novogene aims to support advanced genomic applications that can improve human health and environmental sustainability [3]